Gesynta Pharma Ab Is A Swedish Clinical Stage Pharmaceutical Company Founded In 2017The Company Specializes In Developing Innovative Treatments For Chronic Inflammatory Diseasesfocusing On The Enzyme Microsomal Prostaglandin E Synthase 1Mpges 1 Which Plays A Key Role In Inflammationgesynta Pharma S Research And Development Efforts Are Based On Pioneering Studies From The Karolinska Institutetand Its Leadership Team Has Extensive Experience In Drug Development The Company S Pipeline Includes Vipoglanstatgs 248 Currently In Phase Ii Clinical Trials For Endometriosiswhich Is Designed To Reduce Inflammation And Pain Without Hormonal Side Effectsanother Candidategs 073Is Ready For Phase I Trials And Targets Chronic Inflammatory Paingesynta Pharma Aims To Address Unmet Needs In The Treatment Of Endometriosis And Broader Chronic Inflammatory Conditionswith A Focus On Disease Modifying Therapiesthe Company Has Secured Funding From Various Institutional Investors To Support Its Clinical And Preclinical Development Efforts
